GlycoMimetics Inc. (GLYC) announced after the bell Wednesday that it has been granted Breakthrough Therapy designation by the FDA for GMI-1271 in the treatment of adult relapsed/refractory acute myeloid leukemia.
from RTT - Before the Bell http://ift.tt/2pRTelX
via IFTTT
No comments:
Post a Comment